NFKB1 and neoplasm: Despite the clear potential of STING as an anti-tumor immunity promoting therapeutic target, translation of STING agonists into the clinic has been met with challenges, which are likely associated with narrow therapeutic indices and the potential promotion of NF-κB-related tumorigenic mechanisms28,29.